NFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number		10577470		
	Filing Date		2007-01-11		
	First Named Inventor Matt		tthews		
	Art Unit		1626		
	Examiner Name K		al A. Saeed		
	Attorney Docket Numb	er	007500,00007		

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Par of cited Doc	tentee or Applicant ument	Pages,Columns,Lines where Relevant Passages or Releva Figures Appear		
	1	4591589		1986-05-27	GASC et al.				
	2	7276505		2007-10-02	MATTHEWS				
If you wisi	h to ad	d additional U.S. Pate	nt citatio	n information pl	ease click the	Add button.	_	Add	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document		Releva	,Columns,Lines ant Passages or s Appear	
If you wis	1 h to ad	ld additional U.S. Pub		oplication citation			d buttor	Add	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Name of Patente Applicant of cited Document	e or	Pages,Columns where Relevant Passages or Re Figures Appear	76
	1	97/34893	wo		1997-09-25	Astra Pharmaceuti Lld, and Astra Aktie			
	2	99/00391	wo		1999-01-07	Merck Sharp & Dol Limited	nme		

	3	2004/048378	wo		2004-06-10	Active Biotech AB		
	4	2004/055014	wo		2004-07-01	Active Biotech AB		
	5	2004/081011	wo		2004-09-23	Avidex Limited		
If you wish	to a	dd additional Foreign P	atent Document	citation	information p	lease click the Add buttor	Add	_
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city, and/or country where published.						
	1	APPEL & BROSSART, "Development of Novel Compounds to Treat Autommune and Inflammatory Diseases and Graft Versus Host Reactions," Endoorn, Metab. Immune Disord. Drug Targets No. 7, pp 93-97, 2007						
	2	BRUMEANU et al., "Down-regulation of autoreactive T-cells by HMS CoA reductase inhibitors," Clin. Immunol. Vol. 119, pp 1-12, 2006						
	3	CHITALE & MOOTS, "Abstacept the first T lymphocyte co-dimutation modulator, for the treatment of rheumatoid arthritis," Expert. Opn. Boil. Ther., Vol 8, pp 115-122, 2008						
	4	CHOY, "T Cells in Psoriatic Arthrifis," Curr. Rheumstol. Rep. Vol. 6, pp 437-41, 2007						
	5	COPE et al., "The centra	al role of T cells in	rheuma	toid arthritis," Cl	in. Exp. Rheumatol., Vol. 25	5, pp S4-S11, 2007	
	6					ICAM-1 or B7-1 can costim nol., Vol. 155, pp 45-57, 19		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10577470		
Filing Date		2007-01-11		
First Named Inventor	Matth	Matthews		
Art Unit		1626		
Examiner Name	Kamal A. Saeed			
Attackers Dealest Number		007500 00007		

7	GIMMI et al., "Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation," Immunology, Vol. 90, pp 6586-90, July 1993	
8	KRISTENSEN et al., "The number needed to treat for adalimsurab, elamercopt, and infliximab based on ACR50 response in three randomized controlled thats on established rheumatoid arthritis: a systematic literature review," Sound. J. Rheumatol., Vol. 36, pp 411-417, 2007	
9	LINSLEY et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interieukin 2 mRNA Accumulation," J. Exp. Med. Vol. 173, pp 721-30, March 1991	
10	MALLONE & ENDERT, "T Cells in the Pathogenesis of Type 1 Diabetes," Curr. Diab. Rep., Vol. 8, pp 101-96, 2008	
11	SURESH et al., "Role of C028-87 Interactions in Generation and Maintenance of C08 T Cell Memory," The Journal of Immunology, Vol. 167: pp 5965-5673, 2001	
12	WEISS et al., "Role of CD28-97 Interactions in Generation and Maintenance of CD8 T Cell Memory," Neuroimmunol. Vol. 191, pp 79-85, 2007	
13	Medigene Press Release, "RhuDex(TM) Clinical Development to Continue Following Feedback from Regulatory Authorities," October 5, 2009	
14	COLLINS et al., "The interaction properties of costimulatory molecules revisited," Immunity, Vol. 17, pp. 201-210, 2002	
15	LENSCHOW et al., "CD28/B7 system of T cell costimulation," Annu. Rev. Immunol., Vol. 14, pp. 233-258, 1996	
16	HUXLEY et al., "High-affinity small molecule inhibitors of T cell costmulation," Chem. Biol., Vol. 11, pp 1651-1658, 2004	
17	SALOMON et al., "B7/CD28 coefimulation is essential for the homeodass of the CD4+CD25+ immunoregulatory T cells that control automimune diabetes, immunity, Vol. 12, pp 431-440, 2000	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

plication Number		10577470	
ing Date		2007-01-11	
rst Named Inventor	Matth	Matthews	
t Unit		1626	
caminer Name	Kama	I A. Saeed	
torney Docket Numb	or	007500 00007	

Date Considered

	18	WEST, "Solid state chemistry and its applications," Wiley & Sons, New York, book Chapter 10, pp 358-359, 1988				
	19	GRIESSER, "The Importance of Solvates," Polymorphism in the Pharmazuetical Industry, Chapter 8, pp 211-230, 2008				
	20	STRIETH et al., "Pacifaxel encapsulated in cationic liposomes increases tumor microvesse leakiness and improves therapeutic efficacy in combination with Capitatin," Clin Cancer Res., Vol. 14, No. 14, pp. 4603-4611, 2008				
	21	LUKES et al., "Oral feeding with pig peripheral lymphocytes decreases the xenogeneic delayed type hypersensitivity reaction in galactosyltransferase knockout mice," Abstract, Transplant Proc., Vol. 37, No. 8, pp 3327-3331, 2005				
	22	STRIETH et al., "Tumor-selective vessel occlusions by platelets after vescular targeting chemotherapy using pacitaxel encapsulated in catomic liposomes," Int J Cancer, Vot. 122, No. 2, pp 452-460, 2008				
	23	AMES & BULL, "Preparation of cinnoline-3, 4-dicarbontifile and -dicarboxylic acid," Tetrahedron, Vol. 37, No. 14, pp 2499-2491, 1991				
If you wish to add additional non-patent literature document citation information please click the Add button Add						
FYAMINER SIGNATURE						

F

E

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at wew USPTO_GOV/ or MPEP 90.04. * Enter office that issued the document, by the how-leftor office (WIPO Standard ST.3). **Strain patents per left of Lampares period for Lampares (Lampares Lampares) and the Standard ST.3). **Strain patents are set in the Lampares and Lampares (Lampares Lampares) and Lampares (Lampares) and

Examiner Signature